Literature DB >> 3544539

[Value of sonography in assessing nodular changes of the thyroid in an endemic goiter area].

K Bauch, M Schubert, K F Fuchs, H Döge, G Möckel, H D Spörl, A Dempe.   

Abstract

In an area of endemic goiter 304 patients with an increased thyroid gland were examined by palpation, sonographically and partly scintigraphically. The average age was 37 (12-78) years, the average age of the patients with nodular changes of the thyroid gland 38-44 years. Patients with a diffuse struma were significantly younger with an average age of 33 years. A false-positive enlargement of the thyroid gland established by palpation occurred in 16.1% (n = 49/304). In the sonographic examination 148 out of 304 patients revealed a diffuse enlargement of the thyroid gland without provable nodular change. However, in about one third already more or less clearly characterized regressive changes could be observed. In 156 of the 304 patients 109 times solitary nodes and 47 times multinodular changes were established sonographically. In more than one third of all nodular goiters or one fifth of all patients examined a cyst was demonstrated sonographically. Two thirds of the sonographically established nodular changes were, however, solid. In 53 of all 304 examined patients could sonographically be established additional, unexpected nodes which had escaped the palpation and partly also the scintigraphic investigation. In 14% the node suspected by palpation could not be ascertained sonographically. According to the echo structure echo-poor and echo-equal solid nodes dominated. The frequency of carcinomata of the solid nodes was 6.7%. Apart from 4 echo-poorly and 2 complexly structured nodes a carcinoma of the thyroid gland demonstrated itself sonographically to the same echo. Finally conclusions are drawn for the diagnostics of the thyroid gland in the endemic area of goiter.

Entities:  

Mesh:

Year:  1986        PMID: 3544539

Source DB:  PubMed          Journal:  Z Gesamte Inn Med        ISSN: 0044-2542


  17 in total

1.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

Review 2.  Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology.

Authors:  Nicolas A Giraldo; J David Peske; Catherine Sautès-Fridman; Wolf H Fridman
Journal:  Virchows Arch       Date:  2019-01-10       Impact factor: 4.064

Review 3.  Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer.

Authors:  Matthew R Woeste; Anne E Geller; Robert C G Martin; Hiram C Polk
Journal:  Ann Surg Oncol       Date:  2021-01-03       Impact factor: 5.344

4.  The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.

Authors:  Shogo Kumagai; Yosuke Togashi; Takahiro Kamada; Eri Sugiyama; Hitomi Nishinakamura; Yoshiko Takeuchi; Kochin Vitaly; Kota Itahashi; Yuka Maeda; Shigeyuki Matsui; Takuma Shibahara; Yasuho Yamashita; Takuma Irie; Ayaka Tsuge; Shota Fukuoka; Akihito Kawazoe; Hibiki Udagawa; Keisuke Kirita; Keiju Aokage; Genichiro Ishii; Takeshi Kuwata; Kenta Nakama; Masahito Kawazu; Toshihide Ueno; Naoya Yamazaki; Koichi Goto; Masahiro Tsuboi; Hiroyuki Mano; Toshihiko Doi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Immunol       Date:  2020-08-31       Impact factor: 25.606

Review 5.  Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.

Authors:  Elena María Brozos-Vázquez; Roberto Díaz-Peña; Jorge García-González; Luis León-Mateos; Patricia Mondelo-Macía; María Peña-Chilet; Rafael López-López
Journal:  Cancer Immunol Immunother       Date:  2020-10-28       Impact factor: 6.968

6.  A gene expression-based immune signature for lung adenocarcinoma prognosis.

Authors:  Lijuan Wang; Xizhi Luo; Chao Cheng; Christopher I Amos; Guoshuai Cai; Feifei Xiao
Journal:  Cancer Immunol Immunother       Date:  2020-05-05       Impact factor: 6.968

Review 7.  B cell checkpoints in autoimmune rheumatic diseases.

Authors:  Samuel J S Rubin; Michelle S Bloom; William H Robinson
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

8.  Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Authors:  Takahiro Ebata; Toshio Shimizu; Takafumi Koyama; Akihiko Shimomura; Satoru Iwasa; Shunsuke Kondo; Shigehisa Kitano; Kan Yonemori; Yutaka Fujiwara; Noboru Yamamoto
Journal:  Cancer Chemother Pharmacol       Date:  2019-11-19       Impact factor: 3.333

Review 9.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.

Authors:  Lawrence P Andrews; Hiroshi Yano; Dario A A Vignali
Journal:  Nat Immunol       Date:  2019-10-14       Impact factor: 25.606

Review 10.  The emerging role of epigenetic therapeutics in immuno-oncology.

Authors:  Michael J Topper; Michelle Vaz; Kristen A Marrone; Julie R Brahmer; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2019-09-23       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.